Becotide
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Terms and conditions of storage
Bekotide is an inhaled glucocorticosteroid with anti-inflammatory activity.
Release form and composition
Dosage form - metered dose inhalation aerosol: clear, colorless liquid [200 doses in an aluminum inhaler hermetically sealed with a metering valve, 1 inhaler in a cardboard box (should not show signs of corrosion)].
1 dose of aerosol contains:
- active substance: beclomethasone dipropionate - 0.05 mg or 0.25 mg;
- auxiliary components: anhydrous ethanol, glycerol, norflurane (HFA-134a).
Indications for use
The use of Bekotide is shown as a basic therapy for bronchial asthma.
Contraindications
- age up to 4 years;
- individual intolerance to the components of the drug.
During pregnancy and breastfeeding, the use of the drug is possible if, in the opinion of the doctor, the potential benefit of therapy to the mother outweighs the possible harm to the fetus or child.
Method of administration and dosage
Becotide is intended for inhalation use only. Given the prophylactic focus of the drug, the patient should be informed about the mandatory regular intake of inhalation, regardless of the symptoms of bronchial asthma.
The doctor sets the initial dose of the drug individually, taking into account the severity of the disease.
To obtain an optimal effect during use, the dose is adjusted depending on the response to the drug.
The recommended daily dosage for patients over 12 years of age, taking into account the severity of bronchial asthma:
- mild course: 0.2-0.6 mg, divided into several inhalations;
- moderate course: 0.6-1 mg, divided into several inhalations;
- severe course: 1-2 mg, divided into several inhalations.
For children 4–12 years old, the initial therapeutic dose is up to 0.4 mg per day, divided into several inhalations. The daily dose of beclomethasone should not exceed 0.5 mg.
In renal or hepatic insufficiency and in elderly patients, dose adjustment is not required.
If the patient has difficulty in coordinating the pressure on the inhaler dispenser and inhalation, inhalation can be performed using a spacer. For inhalation of Bekotide in children, it is recommended to use the Bebihaler spacer.
If you need to increase the daily dose, you should consult your doctor.
Side effects
- from the respiratory system: often - irritation of the pharyngeal mucosa, hoarseness; very rarely - paradoxical bronchospasm;
- local reactions: very often - aphthous stomatitis (candidiasis of the oral mucosa and pharynx);
- from the endocrine system: very rarely - a decrease in bone mineral density, Cushing's syndrome, suppression of the adrenal cortex, cushingoid appearance, growth retardation in children;
- allergic reactions: sometimes - itching, rash, erythema, urticaria; very rarely - swelling of the face, eyes, lips, pharynx;
- from the nervous system: very rarely - sleep disturbances, anxiety, behavior changes, irritability and hyperactivity (more often in children);
- on the part of the organs of vision: glaucoma, cataracts.
special instructions
Bekotide is a remedy for regular long-term treatment of bronchial asthma; relief of an acute asthma attack is carried out with inhaled quick-acting bronchodilators. The progression of a sudden worsening of asthma symptoms is a potential threat to the patient's life.
The physician should make sure that inhalation techniques are followed correctly, especially by children.
The effect of treatment must be regularly monitored in order to timely determine the symptoms of a deterioration in the state of respiratory function and revise the dose of the drug, and, if necessary, prescribe systemic glucocorticosteroids (GCS) or antibiotics.
A manifestation of the development of paradoxical bronchospasm is an increase in wheezing after inhalation. To relieve this condition, a fast-acting inhalation bronchodilator is used, the use of Bekotide should be discontinued.
To reduce the irritating effect of the drug on the pharyngeal mucosa, it is recommended to rinse the mouth with water immediately after inhalation or use a spacer.
The likelihood of developing candidiasis of the oral mucosa and pharynx increases with the appointment of daily doses of Bekotide in excess of 0.4 mg. Most often, this complication occurs when the level of antibodies to Candida in the blood is high, indicating a previous infection. To prevent the development of candidiasis, you can rinse your mouth with water after each inhalation. Against the background of ongoing therapy with beclomethasone, the patient should be prescribed the concomitant use of local antifungal agents.
Oral administration of GCS increases the risk of developing systemic side effects, therefore it is important to choose the minimum effective dose for each patient, which ensures adequate control of the course of the disease.
Due to the risk of dysfunction of the adrenal cortex when switching to treatment with Bekotide, the abolition of systemic steroids should be carried out by a gradual decrease in the daily dose. During this period, the patient needs close medical supervision and regular monitoring of adrenal function. In addition, the patient must always have a warning card with him indicating the need for additional administration of systemic glucocorticosteroids in stressful situations.
When allergic rhinitis, eczema and other forms of allergy appear, abrupt discontinuation of the drug is not recommended.
Special care must be taken when treating patients with inactive or active pulmonary tuberculosis.
The product does not contain freon. Even a high concentration of HFA-34a propellant is not toxic.
With prolonged use of the drug by children, regular monitoring of their growth is required.
The influence of Bekotide on the ability to drive vehicles and mechanisms has not been established.
Drug interactions
In especially predisposed patients, the low content of ethanol in the aerosol creates a prerequisite for the theoretical possibility of the drug's interaction with metronidazole or disulfiram.
Terms and conditions of storage
Keep out of the reach of children.
Store at temperatures up to 30 ° C.
Shelf life is 2 years.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
